leisure time -WSS

leisure time

author：knowledge 2025-08-06 04:47:14 - browse：7

he exterior of the U.S. Capitol building is seen at sunrise — Sarah Silbiger/Getty Images

WASHINGTON — Panels in both the House and Senate have now passed restrictions to drug middlemen business practices, increasing the chances of those measures being included in future government spending bills.

The bipartisan reforms to pharmacy benefit managers were among 21 bills that the House Energy & Commerce health subcommittee passed today. The policies are not identical, but at least three PBM reforms have been passed by panels in both chambers:

One that would replace PBM fees that are tied to a percentage of drug prices with flat fees
Another that would require Medicare to create standard performance measures on which PBMs base pharmacy payments
A third that would require PBMs to report a host of information, including drug costs, savings, beneficiary out-of-pocket costs, payments to pharmacies, and the amount of business directed to PBM-owned pharmacies

The Energy & Commerce subcommittee also passed other bills that mirror legislation that Senate Finance also has passed. That includes legislation to ensure seniors pay no more for drugs than insurers, and a measure that lets insurers add less-expensive biosimilars to formularies mid-year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： HIV vaccine remains elusive. Immunologists keep trying new ideas

hotspot

WSS

Cytokinetics CEO stresses company can launch heart drug on its own

The Readout: Lisata, Eisai x Biogen, and the Met Gala (!)

Big Tobacco's 'harm reduction': Is it for real, or a sham?

The cancer stories no one wants to hear

Readers respond to H5N1 and livestock movements, and more

How I helped Pfizer think through the ethics of Viagra

focus

leisure time

hotspot

Hollywood unions extend contract negotiations for actors

Military medical care influenced by rank and race, new study finds

Anesthesiologist group: stop taking Ozempic before surgery

Physicians aren't 'burning out.' They're suffering from moral injury

Anesthesiologist group: stop taking Ozempic before surgery

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Psychedelics group wrestles with new pharma identity

Readout LOUD podcast: Live from STAT Breakthrough Summit West

Medical leaders decry Supreme Court decision on affirmative action

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

explore

Analysis of pharma R&D ranks Novo Nordisk, J&J above their peers

Helping hospitals and community health centers plan for resilience

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Case highlights the risks of experimental stem cell therapy

The cancer stories no one wants to hear

When waiting feels immoral: Empathy in the emergency department

explore

hotspot

focus

focus